{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:30:20Z","timestamp":1792621820559,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Inflammatory myofibroblastic tumor (IMT) is a rare pathological entity first described in 1939. This lesion is most commonly found in the lungs, but cases involving other systems, such as the central nervous system known as intracranial IMT (IIMT), have also been reported. Diagnosis currently relies on pathological results due to the lack of characteristic imaging changes. Surgical resection is an effective treatment, though the disease is invasive and may recur. Previous literature has reported a high level of programmed death 1 (PD-1) expression in IMT tissues, suggesting that immunotherapy may be effective for this condition. In this case report, we present a middle-aged male who received PD-1 inhibitor and oncolytic adenovirus (Ad-TD-nsIL12) treatment after IIMT resection surgery. This successful approach provides a new direction for the treatment of IIMT.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1427554","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:33:11Z","timestamp":1721795591000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of intracranial inflammatory myofibroblastic tumor with PD-L1 inhibitor and novel oncolytic adenovirus Ad-TD-nsIL12: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiao","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihai","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa Chard","family":"Dunmall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Plasma cell granulomas of the lung","volume":"31","author":"Bahadori","year":"1973","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Intracranial plasma cell granuloma","volume":"46","author":"West","year":"1980","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-016-2724-5","article-title":"Intracranial multifocal plasma cell granuloma: a case with multiple operations without recurrence of surgically removed lesions","volume":"158","author":"G\u00fcd\u00fck","year":"2016","journal-title":"Acta Neurochir (Wien)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2176\/nmc.38.292","article-title":"Plasma cell granuloma extending from the extracranial to the intracranial space associated with Epstein-Barr virus infection","volume":"38","author":"Fukunaga","year":"1998","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e2021254","DOI":"10.4322\/acr.2021.254","article-title":"Intracranial Inflammatory Myofibroblastic Tumor: A Review of 49 cases","volume":"11","author":"Phogat","year":"2021","journal-title":"Autops Case Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0034-6","article-title":"PD-L1 expression in inflammatory myofibroblastic tumors","volume":"31","author":"Cottrell","year":"2018","journal-title":"Mod Pathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.3390\/cells9112438","article-title":"A Tumor-Targeted Replicating Oncolytic Adenovirus Ad-TD-nsIL12 as a Promising Therapeutic Agent for Human Esophageal Squamous Cell Carcinoma","volume":"9","author":"Zhang","year":"2020","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000213393.57322.c7","article-title":"Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases","volume":"31","author":"Coffin","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199112000-00005","article-title":"Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor","volume":"15","author":"Meis","year":"1991","journal-title":"Am J Surg Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2016.04.011","article-title":"An isolated inflammatory myofibroblastic tumor of adrenal gland","volume":"25","author":"Al Sannaa","year":"2016","journal-title":"Ann Diagn Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annpat.2012.07.006","article-title":"[New WHO classification of tumours of soft tissue and bone]","volume":"32","author":"Coindre","year":"2012","journal-title":"Ann Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199508000-00001","article-title":"Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases","volume":"19","author":"Coffin","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000058","article-title":"Inflammatory myofibroblastic tumor of the orbit: a case report","volume":"31","author":"Cramer","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.01.155","article-title":"Intracranial Inflammatory Myofibroblastic Tumor with Negative Expression of Anaplastic Lymphoma Kinase: A Case Report and Review of the Literature","volume":"125","author":"Wang","year":"2019","journal-title":"World Neurosurg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64550-6","article-title":"TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors","volume":"157","author":"Lawrence","year":"2000","journal-title":"Am J Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/path.4836","article-title":"ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma","volume":"241","author":"Lee","year":"2017","journal-title":"J Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2015.12.005","article-title":"Inflammatory Myofibroblastic Tumors: Current Update","volume":"54","author":"Surabhi","year":"2016","journal-title":"Radiol Clin North Am"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.02.014","article-title":"Fusion of dynactin 1 to anaplastic lymphoma kinase in inflammatory myofibroblastic tumor","volume":"43","author":"Wang","year":"2012","journal-title":"Hum Pathol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.3390\/diagnostics13172725","article-title":"Intracranial Inflammatory Myofibroblastic Tumor: A Literature Review and a Rare Case Misdiagnosed as Acoustic Neuroma","volume":"13","author":"Zhou","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1526","article-title":"Imaging features of meningeal inflammatory myofibroblastic tumor","volume":"30","author":"Kim","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2017.1279645","article-title":"Spontaneous regression of inflammatory myofibroblastic tumor of the orbit: A case report and review of literature","volume":"36","author":"Habib","year":"2017","journal-title":"Orbit"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-003-0109-z","article-title":"Plasma cell granuloma involving the brain and the lung","volume":"145","author":"Greiner","year":"2003","journal-title":"Acta Neurochir (Wien)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2007.04.012","article-title":"PD-1 and its ligands in T-cell immunity","volume":"19","author":"Keir","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/embj.1992.11.issue-11","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003496","article-title":"The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo","volume":"187","author":"Paterson","year":"2011","journal-title":". J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.11.001","article-title":"Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment","volume":"46","author":"D\u2019Angelo","year":"2015","journal-title":"Hum Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1278100","DOI":"10.1080\/2162402X.2016.1278100","article-title":"PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas","volume":"6","author":"Bertucci","year":"2017","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12885-016-2451-6","article-title":"Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/v7112914","article-title":"Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors","volume":"7","author":"Rajani","year":"2015","journal-title":"Viruses"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting T Cell Co-receptors for Cancer Therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ebiom.2018.04.020","article-title":"Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy","volume":"31","author":"Achard","year":"2018","journal-title":"EBioMedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jitc-2021-004167","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.283","article-title":"Intelligent design: combination therapy with oncolytic viruses","volume":"18","author":"Ottolino-Perry","year":"2010","journal-title":"Mol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1066961","DOI":"10.1080\/2162402X.2015.1066961","article-title":"Oncolytic immunotherapy: The new clinical outbreak","volume":"5","author":"Fonteneau","year":"2016","journal-title":"Oncoimmunology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1412902","article-title":"TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"Oncoimmunology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-020-0549-2","article-title":"Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours","volume":"4","author":"Mansurov","year":"2020","journal-title":"Nat BioMed Eng"},{"key":"B45","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1427554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:33:14Z","timestamp":1721795594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1427554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2024.1427554"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1427554","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"article-number":"1427554"}}